Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade

Abdul Shahid Poovathum Parambil, Abul Hussain Mirsa, Azgar Abdul Rasheed, Arun Vasudevan · 2026

Read Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade by Abdul Shahid Poovathum Parambil, Abul Hussain Mirsa, Azgar Abdul Rasheed, Arun Vasudevan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13597254.txt.

Description

Abdul Shahid Poovathum Parambil and co-workers report real-world results of dual HER2 blockade before breast cancer surgery in India, in a 2026 paper. This aggressive cancer subtype responds well to paired targeted drugs plus chemotherapy in trials. Evidence from routine Indian practice was missing.

Seventy-four patients at a Kerala hospital received the two drugs by vein or under the skin. Just over half achieved complete disappearance of invasive cancer in the surgical specimen. The under-skin group scored lower than the vein group, though the gap was not quite significant. Disease stage predicted response in adjusted analysis. The authors present the results as a benchmark for local practice.

Catalog record

CREATORAbdul Shahid Poovathum Parambil, Abul Hussain Mirsa, Azgar Abdul Rasheed, Arun Vasudevan
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13597254

Browse the full library · About the Tower of Babel